Last updated: May 9, 2025
Sponsor: Vertex Pharmaceuticals Incorporated
Overall Status: Completed
Phase
1
Condition
Pain
Treatment
SUZ
Clinical Study ID
NCT06834009
VX24-548-020
Ages 25-80 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Key Inclusion Criteria:
- Panelists are qualified based on training and experience. They will be required todetect, identify, recognize, and accurately describe different taste elements andflavor combinations.
Exclusion
Key Exclusion Criteria:
History of any illness or clinical condition that, in the opinion of theinvestigator, might confound the results of the study or pose an additional risk tothe participant
Sensitivity to SUZ
Pregnant, nursing, or planning to become pregnant during the study
Other protocol defined Inclusion/Exclusion criteria may apply.
Study Design
Total Participants: 10
Treatment Group(s): 1
Primary Treatment: SUZ
Phase: 1
Study Start date:
March 10, 2025
Estimated Completion Date:
April 24, 2025
Study Description
Connect with a study center
Senopsys, LLC
Woburn, Massachusetts 01801
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.